Genome Institute of Singapore Purchases Four Additional Illumina, Inc. Genome Analyzers To Advance Stem Cell And Cancer Research Studies

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that the Genome Institute of Singapore (GIS), a flagship institution of Singapore and one of the top research centers in the world, has purchased four additional Genome Analyzers taking its installed base to six. Among researchers at GIS, the Genome Analyzer continues to be the preferred platform for conducting sequencing studies. The Genome Analyzers will be used in a variety of projects, including the construction of transcriptional networks linked to cancer and stem cells.